These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. Cantini F; Niccoli L; Matarrese D; Nicastri E; Stobbione P; Goletti D J Infect; 2020 Aug; 81(2):318-356. PubMed ID: 32333918 [TBL] [Abstract][Full Text] [Related]
4. Baricitinib for COVID-19: a suitable treatment? Favalli EG; Biggioggero M; Maioli G; Caporali R Lancet Infect Dis; 2020 Sep; 20(9):1012-1013. PubMed ID: 32251638 [No Abstract] [Full Text] [Related]
5. Baricitinib for COVID-19: a suitable treatment? - Authors' reply. Richardson PJ; Corbellino M; Stebbing J Lancet Infect Dis; 2020 Sep; 20(9):1013-1014. PubMed ID: 32251639 [No Abstract] [Full Text] [Related]
6. Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19? Raschi E; Caraceni P; Poluzzi E; De Ponti F Expert Opin Drug Saf; 2020 Oct; 19(10):1367-1369. PubMed ID: 32840116 [No Abstract] [Full Text] [Related]
7. Mesenchymal stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects. Chen X; Shan Y; Wen Y; Sun J; Du H J Infect; 2020 Oct; 81(4):647-679. PubMed ID: 32422152 [No Abstract] [Full Text] [Related]
8. Can artificial intelligence identify effective COVID-19 therapies? Schultz MB; Vera D; Sinclair DA EMBO Mol Med; 2020 Aug; 12(8):e12817. PubMed ID: 32569446 [TBL] [Abstract][Full Text] [Related]
9. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Richardson P; Griffin I; Tucker C; Smith D; Oechsle O; Phelan A; Rawling M; Savory E; Stebbing J Lancet; 2020 Feb; 395(10223):e30-e31. PubMed ID: 32032529 [No Abstract] [Full Text] [Related]
10. Tele-rounding in a university hospital pulmonary ward during the COVID-19 pandemic: a pilot study. Renner A; Paajanen J; Reijula J Infect Dis (Lond); 2020 Sep; 52(9):669-670. PubMed ID: 32516031 [No Abstract] [Full Text] [Related]
12. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19. Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562 [TBL] [Abstract][Full Text] [Related]
13. Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19. Praveen D; Puvvada RC; M VA Int J Antimicrob Agents; 2020 May; 55(5):105967. PubMed ID: 32259575 [TBL] [Abstract][Full Text] [Related]
14. Pilot virtual clerkship curriculum during the COVID-19 pandemic: Podcasts, peers and problem-solving. Geha R; Dhaliwal G Med Educ; 2020 Sep; 54(9):855-856. PubMed ID: 32418290 [No Abstract] [Full Text] [Related]
15. Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study. Pallotto C; Suardi LR; Esperti S; Tarquini R; Grifoni E; Meini S; Valoriani A; Di Martino S; Cei F; Sisti E; Piani F; Botta A; Salomoni E; Baragli F; Blanc P Infect Dis (Lond); 2020 Sep; 52(9):675-677. PubMed ID: 32543971 [No Abstract] [Full Text] [Related]
16. The Impact of COVID-19 on Italy: A Lesson for the Future. Santacroce L; Bottalico L; Charitos IA Int J Occup Environ Med; 2020 Jul; 11(3):151-152. PubMed ID: 32225178 [No Abstract] [Full Text] [Related]
17. An international, multicentre survey of echocardiographic abnormalities in COVID-19 patients. Ng ACT; Delgado V; Bax JJ Eur Heart J Cardiovasc Imaging; 2020 Sep; 21(9):959-960. PubMed ID: 32729899 [No Abstract] [Full Text] [Related]